Endonovo Therapeutics Inc (OTCMKTS: ENDV) has been seeing higher highs and higher lows since reversing off a dime earlier this year.
Microcapdaily has been reporting on ENDV for years stating back in 2015 – Endonovo Therapeutics Inc has seen a recent explosive surge in volume and price of its $0.052 lows. The move up comes on the heels of ENDV announcement that they are developing a next-generation, off-the-shelf treatment for Graft-Versus-Host Disease (GVHD) using Cytotronics(TM) expanded and ex vivo enhanced stem cells from the human umbilical cord.
Endonovo Therapeutics Inc (OTCMKTS: ENDV) is a commercial-stage developer of non-invasive wearable Electroceuticals™ Therapies. The Company’s current portfolio of commercial and clinical-stage wearable Electroceuticals™ Therapies addresses wound healing, pain, post-surgical pain and edema, cardiovascular disease, chronic kidney disease, and Central Nervous System (CNS) Disorders, including traumatic brain injury (TBI), acute concussions, post-concussion syndrome and multiple sclerosis. There is a lot to get excited about on ENDV; this is a commercial-stage developer of non-invasive wearable Electroceuticals™ Therapies, already doing sales with a number of important distribution agreements in place.
Endonovo non-invasive Electroceutical™ System device, SofPulse®, using pulsed short-wave radiofrequency at 27.12 MHz has been FDA-Cleared and CE Marked for the palliative treatment of soft tissue injuries and post-operative pain and edema, and has CMS National Coverage for the treatment of chronic wounds. The Company’s current portfolio of pre-clinical stage Electroceuticals™ addresses chronic kidney disease, liver disease non-alcoholic steatohepatitis (NASH), cardiovascular and peripheral artery disease (PAD), and ischemic stroke. The Company’s non-invasive, wearable Electroceuticals™ work by restoring key electrochemical processes that initiate anti-inflammatory and growth factor cascades necessary for healing to occur.
Last year ENDV announced the first commercial sales of SofPulse™, its non-invasive, wearable Electroceutical™ device. SofPulse™ is the Company’s FDA-Cleared Electroceutical™ System for the palliative treatment of post-operative pain and edema in superficial soft tissues. Furthermore, the Company announced it is seeking distribution partners in Europe for SofPulse™, which is CE-Marked for the promotion of wound healing, reduction of pain and post-operative edema.
To Find out the inside Scoop on ENDV Subscribe to Microcapdaily.com Right Now by entering your Email in the box below
Recently ENDV has signed a number of distribution agreement for the distribution of SofPulse™, its non-invasive Electroceutical™ Therapy for post-operative pain relief and reduction of swelling. The Company signed agreements with Plagens Medical Consultants as well as Magniant, LLC which includes sales, marketing and distribution targeting the VA, DOD, Indian Health Services, Long Term Care Institutions, Pain Clinics, Wound Clinics and Private Practices among physicians.
Last week ENDV announced the addition of eight new hospitals Endonovo’s SofPulse® medical device is approved for use. The eight hospitals are located in the following geographic areas: 7 Hospitals in Nevada and 1 Hospital in North Carolina.
Endonovo CEO Alan Collier states, “Our Endonovo sales and marketing team continues to expand distribution by working with hospital administrators and medical professionals daily. Adding eight additional hospitals to our distribution network demonstrates SofPulse® marketing efforts are consistently striving to bring this innovative postoperative pain and edema reduction device to the public. Making the SofPulse® device available to every patient having a surgical procedure is our nationwide marketing goal to help resolve the opioid crisis gripping America. With the incredible health benefits SofPulse® provides we are excited about the progress and the strong positive market feedback we have been receiving regarding the demand and need for SofPulse® in hospitals nationwide.”
We have a Monster Pick Coming. Subscribe Right Now!
Currently trading at a $1.3 million market valuation ENDV has $665k in the treasury, significant debt and reported revenues of $161k for the 9 months ended September, 30, 2019. ENDV is an exciting story in small caps: ENDV is a commercial-stage developer of non-invasive wearable Electroceuticals™ Therapies, already doing sales with a number of important distribution agreements in place. The Company continues developing a portfolio of commercial and clinical-stage wearable Electroceuticals™ Therapies addresses wound healing, pain, post-surgical pain and edema, cardiovascular disease, chronic kidney disease, and Central Nervous System (CNS) Disorders, including traumatic brain injury (TBI), acute concussions, post-concussion syndrome and multiple sclerosis. We will be updating on ENDV when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with ENDV.
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Disclosure: we hold no position in ENDV either long or short and we have not been compensated for this article.